Rostock R A, Klein J L, Leichner P, Kopher K A, Order S E
Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1345-50. doi: 10.1016/0360-3016(83)90266-3.
The in vivo localization of 131I-radiolabeled antiferritin and normal IgG in the H-4-II-E rat hepatoma model was investigated by serial necropsy. Groups of 14 to 18 animals were injected with 500 microCi (200 micrograms) of normal and antiferritin IgG. The total dose from the nonpenetrating beta radiation was calculated for tumor and normal tissue, and expressed as a targeting ratio of antiferritin to normal IgG for each organ studied. The results demonstrate 2.9 times greater dose deposition in tumors of animals treated with 131I-antiferritin than with 131I-normal IgG. 131I-antiferritin deposited equivalently in primary tumors and metastatic lesions of similar size. The specific binding in tumors could be competitively inhibited by the addition of unlabeled antiferritin but not unlabeled normal IgG. Specific targeting with 131I-antiferritin comparison to 131I-normal IgG did not occur in any normal tissue. There was considerable variation in the dose deposition in different normal tissues.
通过连续尸检研究了131I标记的抗铁蛋白和正常IgG在H-4-II-E大鼠肝癌模型中的体内定位。将14至18只动物分为几组,分别注射500微居里(200微克)的正常IgG和抗铁蛋白IgG。计算肿瘤和正常组织中非穿透性β辐射的总剂量,并表示为所研究每个器官中抗铁蛋白与正常IgG的靶向比率。结果表明,用131I-抗铁蛋白处理的动物肿瘤中的剂量沉积比用131I-正常IgG处理的动物高2.9倍。131I-抗铁蛋白在大小相似的原发性肿瘤和转移灶中的沉积量相当。添加未标记的抗铁蛋白可竞争性抑制肿瘤中的特异性结合,但添加未标记的正常IgG则不能。与131I-正常IgG相比,131I-抗铁蛋白在任何正常组织中均未发生特异性靶向。不同正常组织中的剂量沉积存在相当大的差异。